- Ovarian Cancer https://criscancer.org/en/research-projects/cris-funding-projects/cic-ovarian-cancer/ Ovarian Cancer
- Ovarian Cancer https://criscancer.org/en/research-projects/cris-funding-projects/cic-ovarian-cancer/ Principal Investigators: Dr Alberto Ocaña and Dr Atanasio Pandiella. Centres: Albacete University Hospital Complex, CHUA and Cancer Research Centre (Centro de Investigación del Cáncer - CIC), Salamanca. Background Ovarian cancer is a very frequent ...
Principal Investigators: Dr Alberto Ocaña and Dr Atanasio Pandiella.
Centres: Albacete University Hospital Complex, CHUA and Cancer Research Centre (Centro de Investigación del Cáncer – CIC), Salamanca.
Ovarian cancer is a very frequent type of tumour in women. In fact, it represents the 6th most frequent tumour, and its incidence is increasing every year in Spain. It has a high mortality rate, as there are no early reliable detection methods and it is usually diagnosed when it has already spread.
The groups headed by Alberto Ocaña and Atanasio Pandiella in Salamanca collaborate in the search for new treatment alternatives for these tumours. Based on tumour samples, or on information taken from international databases, bioinformatics analyses are performed to search for patterns or specific genetic alterations that:
– Set a possible new therapeutic target.
– Explain resistance mechanisms to therapies used in clinical practice.
– Characterise the tumours of patients who respond to treatments and those who don’t.
– Define action mechanisms of new drugs under development, in order to accelerate their development and optimisation.
Once the bioinformatics analyses are performed, their results are checked and validated by means of laboratory experiments on cell lines and animals.
Achievements in the past year
The group has published two significant scientific papers regarding Bet-type protein inhibitors, which have been shown to be very effective against ovarian tumour cells. They have also shown the effectiveness of a new combination of compounds, called Aurora A and CHEK1 inhibitors. These results are important, as around 10% of women suffering from ovarian cancer have the Aurora A and CHEK1 mutations.